CEACAM6 and acute lymphoblastic leukemia: Since both CD66c and CD123 are not expressed by normal BCPs but aberrantly expressed in a subset of BCP-ALL patients (CD66c-positivity: 36–81% [65,66,67,68,69], CD123-positivity: 85% [77]), these markers were combined in the PE-channel.